Who supplies Abbott, who buys from it, and who competes with it. Membership is a disclosed business relationship, not a keyword match, and every row carries the sentence that proves it.
⚡
Supply Chain & Partner Read-Through EngineActive
Proactive revenue read-through alerts whenever Abbott files 8-Ks, announces contracts, or beats guidance.
12 companies with a disclosed relationship to Abbott
| Ticker | Relationship | Role | Price | Market Cap | P/E | 1D | From High | Mentions | Catalyst Materiality | Alert |
|---|---|---|---|---|---|---|---|---|---|---|
| Retail Channel (2) | ||||||||||
| WMT | Retail distribution | channel | - | - | - | - | - | 20 | 15% exp77 | |
| CVS | Retail pharmacy distribution | channel | - | - | - | - | - | 5 | 15% exp77 | |
| Pharma Counterparties (1) | ||||||||||
| LLY | Diabetes care adjacency | partner | - | - | - | - | - | 15 | 15% exp77 | |
| Devices & Supplies (1) | ||||||||||
| BDX | Medical supplies adjacency | supplier | - | - | - | - | - | 12 | 15% exp77 | |
| Diagnostics (1) | ||||||||||
| TMO | Diagnostics | competitor | - | - | - | - | - | 3 | 15% exp77 | |
| Payers & PBMs (1) | ||||||||||
| UNH | Device reimbursement | channel | - | - | - | - | - | 1 | 15% exp77 | |
| Competitor (6) | ||||||||||
| DXCM | Continuous glucose monitoring | competitor | - | - | - | - | - | 80 | 20% exp79 | |
| JNJ | Devices and diagnostics | competitor | - | - | - | - | - | 42 | 20% exp79 | |
| EW | Structural heart | competitor | - | - | - | - | - | 30 | 20% exp79 | |
| SYK | Medical devices | competitor | - | - | - | - | - | 21 | 15% exp77 | |
| MDT | Medical devices and diabetes | competitor | - | - | - | - | - | 6 | 15% exp77 | |
| BSX | Cardiovascular devices | competitor | - | - | - | - | - | 1 | 15% exp77 | |
Every row is backed by a quote from an earnings call or an SEC filing. Mentions counts how often the relationship is named across the last four quarters, which is why the most dependent companies sort to the top of each group. Catalyst Materiality computes hardware bottleneck exposure and priority.